Nutraceuticals and dietary supplements to improve quality of life and outcomes in heart failure patients

Current Pharmaceutical Design

Volumn 23, Issue 8, 2017, Pages 1265-1272

  Cicero, Arrigo F G ^a   Colletti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Coenzyme Q10; D ribose; Dietary supplements; Hawthorn; Heart failure; L carnosine; Nutraceuticals; Probiotics

Indexed keywords

CARNITINE; CARNOSINE; NITRIC ACID DERIVATIVE; OMEGA 3 FATTY ACID; PROBIOTIC AGENT; RIBOSE; UBIDECARENONE; VITAMIN D;

CAUSE OF DEATH; CRATAEGUS; DIET SUPPLEMENTATION; DISEASE PREDISPOSITION; FOLLOW UP; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; MITOCHONDRIAL PERMEABILITY; NEW YORK HEART ASSOCIATION CLASS; PHYTOCHEMISTRY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; DIETARY SUPPLEMENT; PSYCHOLOGY; TREATMENT OUTCOME;

DIETARY SUPPLEMENTS; HEART FAILURE; HUMANS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 85020906323     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666170124120518     Document Type: Review

References (98)

1. Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/ AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e1-e82.
2. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016
3. Mozaffarian D, Benjamin EJ, Go AS, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016; 133: e38-e360.
4. Liu L, Eisen HJ. Epidemiology of heart failure and scope of the problem. Cardiol Clin 2014; 32(1): 1-8.
5. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8: 30-41.
6. Maggioni AP. Epidemiology of Heart Failure in Europe. Heart Fail Clin 2015; 11(4): 625-35.
7. Meyer S, Brouwers FP, Voors AA, et al. Sex differences in newonset heart failure. Clin Res Cardiol 2015; 104(4): 342-50.
8. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000; 5(2): 167-73.
9. ACCF/AHA Guideline for the Management of Heart Failure 2013. J Am Coll Cardiol 2013; 62(16): e147-e239.
10. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-847.
11. Rifai L, Silver MA. A Review of the DASH Diet as an optimal dietary plan for symptomatic heart failure. Prog Cardiovasc Dis 2016; 58(5): 548-54.
12. Rifai L, Pisano C, Hayden J, et al. Impact of the DASH diet on endothelial function, exercise capacity, and quality of life in patients withheart failure. Proc (Bayl Univ Med Cent) 2015; 28(2): 151-6.
13. Tektonidis TG, Akesson A, Gigante B, et al. Adherence to a Mediterranean diet is associated with reduced risk of heartfailure in men. Eur J Heart Fail 2016; 18(3): 253-9.
14. Salehi-Abargouei A, Maghsoudi Z, Shirani F, et al. Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases--incidence: a systematic review and meta-analysis on observational prospective studies. Nutrition 2013; 29(4): 611-8.
15. Wexler R, Pleister A, Raman SV, et al. Therapeutic lifestyle changes for cardiovascular disease. Phys Sports Med 2012; 40: 109-15.
16. Cicero AF, Borghi C. Evidence of clinically relevant efficacy for dietary supplements and nutraceuticals. Curr Hypertens Rep 2013; 15(3): 260-7.
17. Vasanthi HR, Shri Shri Mal N, Das DK. Phytochemicals from plants to combat cardiovascular disease. Curr Med Chem 2012; 19(14): 2242-51.
18. Witte KK, Clark AL. Chronic heart failure and multiple micronutrient supplementation: realistic hope or idealistic conjecture? Heart Fail Monit 2005; 4(4): 123-9.
19. Ford E, Adams J, Graves N. Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia. BMJ Open 2012; 2(5). pii: e001094.
20. Koch E, Malek FA. Standardized extracts from hawthorn leaves and flowers in the treatment of cardiovascular disorders--preclinical and clinical studies. Planta Med 2011; 77(11): 1123-8.
21. Crataegus Oxyacantha (Hawthorn). Monograph. Altern Med Rev 2010; 15(2): 164-7.
22. Holubarsch CJ, Colucci WS, Meinertz T, et al. Survival and Prognosis: Investigation of Crataegus Extract WS 1442 in CHF (SPICE) trial study group. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail 2008; 10(12): 1255-63.
23. Willer EA, Malli R, Bondarenko AI, et al. The vascular barrierprotecting hawthorn extract WSR 1442 raises endothelial calcium levels by inhibition of SERCA and activation of the IP3 pathway. J Mol Cell Cardiol 2012; 53(4): 567-77.
24. Rigelsky JM, Sweet BV. Hawthorn: pharmacology and therapeutic uses. Am J Health Syst Pharm 2002; 59: 417-22.
25. Wang J, Xiong X, Feng B. Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach. Evid Based Complement Alternat Med 2013; 2013: 149363.
26. Pittler MH, Guo R, Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev 2008; 1: CD005312.
27. Eggeling T, Regitz-Zagrosek V, Zimmermann A, Burkart M. Baseline severity but not gender modulates quantified Crataegus extracteffects in early heart failure--a pooled analysis of clinical trials. Phytomedicine 2011; 18(14): 1214-9.
28. Molyneux SL, Florkowski CM, Lever M, et al. Biological variation of coenzyme Q10. Clin Chem 2005; 51(2): 455-7.
29. Crane FL, Hatefi Y, Lester RL, et al. Isolation of a quinone from beef heart mitochondria. 1957. Biochim Biophys Acta 1989; 1000: 362-3.
30. Menke T, Niklowitz P, de Sousa G, et al. Comparison of coenzyme Q10 plasma levels in obese and normal weight children. Clin Chim Acta 2004; 349(1-2): 121-7.
31. Florkowski CM, Molyneux SL, Young JM. Coenzyme Q10 and congestive heart failure: an evolving evidence base. Kardiol Polska 2015; 73(2): 73-79.
32. Weis M, Mortensen SA, Rassing MR, et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med 1994; 15 (Suppl): s273-80.
33. Miles MV, Horn P, Miles L et al. Bioequivalence of coenzyme Q10 from over-the-counter supplements. Nutr Res 2002; 22: 919-29.
34. Kumar S, Rao R, Kumar A, et al. Novel carriers for coenzyme Q10 delivery. Curr Drug Deliv 2016; 13(8): 1184-204.
35. Weber C, Bysted A, Hłlmer G. The coenzyme Q10 content of the average Danish diet. Int J Vitam Nutr Res 1997; 67(2): 123-9.
36. Folkers K, Wolaniuk J, Simonsen R, et al. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc Natl Acad Sci USA 1985; 82(13): 4513-6.
37. Onur S, Niklowitz P, Jacobs G, et al. Association between serum level of ubiquinol and NT-proBNP, a marker for chronic heart failure, in healthy elderly subjects. Biofactors 2015; 41(1): 35-43.
38. DiNicolantonio JJ, Bhutani J, McCarty MF, et al. Coenzyme Q10 for the treatment of heart failure: a review of the literature. Open Heart 2015; 2(1): e000326.
39. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 1997; 18 (Suppl): S159-68.
40. Sander S, Coleman CI, Patel AA, et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 2006; 12: 464-72.
41. Fotino AD, Thompson-Paul AM, Bazzano LA. Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis. Am J Clin Nutr 2013; 97: 268-75.
42. Mortensen SA, Rosenfeldt F, Kumar A, et al. Q-SYMBIO Study Investigators. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail 2014; 2(6): 641-9.
43. Nagatomo Y, Tang WH. Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis. J Cardiol Fail 2015; 21(12): 973-80.
44. Sandek A., Bauditz J., Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1561-9.
45. Sandek A, Bjarnason I, Volk HD, et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol 2012; 157(1): 80-5.
46. Krack A, Sharma R, Figulla HR, et al. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 2005; 26(22): 2368-74.
47. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63.
48. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19: 576-85.
49. Wilson TWH, Zeneng W, Yiying F, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure. J Am Coll Cardiol 2014; 64(18): 1908-14.
50. Costanza AC, Moscavitch SD, Faria Neto HC, et al. Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial. Int J Cardiol 2015; 179: 348-50.
51. Gan XT, Ettinger G, Huang CX, et al. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ Heart Fail 2014; 7(3): 491-9.
52. Boldyrev AA, Aldini G, Derave W. Physiology and pathophysiology of carnosine. Physiol Rev 2013; 93: 1803-45.
53. Sale C, Saunders B, Harris RC. Effect of beta-alanine supplementation on muscle carnosine concentrations and exercise performance. Amino Acids 2010; 39: 321-33
54. Kohen R, Yamamoto Y, Cundy KC, et al. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc Natl Acad Sci USA 1988; 85: 3175-9.
55. Pavlov AR, Revina AA, Dupin AM, et al. The mechanism of interaction of carnosine with superoxide radicals in water solutions. Biochim Biophys Acta 1993; 1157: 304-12.
56. Zaloga GP, Roberts PR, Black KW, et al. Carnosine is a novel peptide modulator of intracellular calcium and contractility in cardiac cells. Am J Physiol 1997; 272(1 Pt 2): H462-8.
57. McCarty MF, Di Nicolantonio JJ. β-Alanine and orotate as supplements for cardiac protection. Open Heart 2014; 1(1): e000119.
58. Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007; 93: 903-7.
59. Zhao Y, Zhao B. Protective effect of natural antioxidants on heart against ischemia-reperfusion damage. Curr Pharm Biotechnol 2010; 11: 868-74.
60. Stvolinsky SL, Dobrota D. Anti-ischemic activity of carnosine. Biochemistry 2000; 65: 849-55.
61. Bokeriya LA, Boldyrev AA, Movsesyan RR, et al. Cardioprotective effect of histidine-containing dipeptides in pharmacological cold cardioplegia. Bull Exp Biol Med 2008; 145: 323-7.
62. Lombardi C, Carubelli V, Lazzarini V, et al. Effects of oral amino Acid supplements on functional capacity in patients with chronic heart failure. Clin Med Insights Cardiol 2014; 8: 39-44.
63. Rosenfeldt FL. Metabolic supplementation with orotic acid and magnesium orotate. Cardiovasc Drugs Ther 1998; 12(Suppl 2): 147-52.
64. Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). Int J Cardiol 2009; 134: 145-7.
65. Artioli GG, Gualano B, Smith A, et al. Role of beta-alanine supplementation on muscle carnosine and exercise performance. Med Sci Sports Exerc 2010; 42: 1162-73.
66. Decombaz J, Beaumont M, Vuichoud J, et al. Effect of slow-release beta-alanine tablets on absorption kinetics and paresthesia. AminoAcids 2012; 43: 67-76.
67. Dalbeni A, Delva P, Minuz P. Could vitamin D supplements be a new therapy for heart failure? Possible pathogenic mechanisms from data of intervention studies. Am J Cardiovasc Drugs 2014; 14(5): 357-66.
68. Gotsman I, Shauer A, Zwas DR, et al. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. Eur J Heart Fail 2012; 14: 357-66.
69. Liu LC, Voors AA, van Veldhuisen DJ, et al. Vitamin D status and outcomes in heart failure patients. Eur J Heart Fail 2011; 13: 619-25.
70. Gullestad L, Ueland T, Vinge LE, et al. Inflammatory cytokines in heart failure: mediators and markers. Cardiology 2012; 122: 23-35.
71. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83: 754-9.
72. Witham MD, Crighton LJ, Gillespie ND, et al. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail 2010; 3: 195-201.
73. Dalbeni A, Scaturro G, Degan M, et al. Effects of six months of vitamin D supplementation in patients with heart failure: a randomized double-blind controlled trial. Nutr Metab Cardiovasc Dis 2014; 24(8): 861-8.
74. Jiang WL, Gu HB, Zhang YF, et al. Vitamin D supplementation in the treatment of chronic heart failure: a meta-analysis of randomized controlled trials. Clin Cardiol 2016; 39(1): 56-61.
75. Ingwall J, Weiss R. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004; 95: 135-4.
76. St Cyr J, Bianco R, Schneider J, et al. Enhanced high energy phosphate recovery with ribose infusion after global myocardial ischemia in a canine model. J Surg Res 1989; 46: 157-62.
77. Ibel H, Zimmer H. Metabolic recovery following temporary regional myocardial ischemia in the rat. J Mol Cell Cardiol 1986; 18(Suppl 4): 61-5.
78. Schneider J, St Cyr J, Mahoney J, et al. Recovery of ATP and return of function after global ischemia. Circulation 1985; 72: (Suppl) III-298.
79. Bayram M, St. Cyr JA, Abraham WT. D-ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study. Ther Adv Cardiovasc Dis 2015; 9(3): 56-65.
80. Khairallah RJ, Sparagna GC, Khanna N, et al. Dietary supplementation with docosahexaenoic acid, but not eicosapentaenoic acid, dramatically alters cardiac mitochondrial phospholipid fatty acid composition and prevents permeability transition. Biochim Biophys Acta 2010; 1797: 1555-62.
81. Khairallah RJ, Kim J, O’Shea KM, et al. Improved mitochondrial function with diet induced increase in either docosahexaenoic acid or arachidonic acid in membrane phospholipids. PLoS One 2012; 7: e34402.
82. O’shea KM, Khairallah RJ, Sparagna GC, et al. Dietary omega 3 fatty acids alter cardiac mitochondrial phospholipid composition and delay Ca2+ induced permeability transition. J Mol Cell Cardiol 2009; 47: 819-27.
83. Galvao TF, Khairallah RJ, Dabkowski ER, et al. Marine n3 polyunsaturated fatty acids enhance resistance to mitochondrial permeability transition in heart failure, but do not improve survival. Am J Physiol Heart Circ Physiol 2013; 73: H12-21.
84. Stanley WC, Khairallah RJ, Dabkowski ER. Update on lipids and mitochondrial function: impact of dietary n 3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 2012; 15: 122-6.
85. Chrysohoou C, Metallinos G, Georgiopoulos G, et al. Short term omega-3 polyunsaturated fatty acid supplementation induces favorable changes in right ventricle function and diastolic filling pressure in patients with chronic heart failure; A randomized clinical trial.Vascul Pharmacol 2016; 79: 43-50.
86. Dabkowski ER, O'Connell KA, Xu W, et al. Docosahexaenoic acid supplementation alters key properties of cardiac mitochondria and modestly attenuates development of left ventricular dysfunction in pressure overload-induced heart failure. Cardiovasc Drugs Ther 2013; 27(6): 499-510.
87. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9645): 1223-30.
88. Ghio S, Scelsi L, Latini R, et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail 2010; 12(12): 1345-53.
89. Moertl D, Hammer A, Steiner S, et al. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of non ischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J 2011; 161(5): 915.e1-9.
90. Coggan AR, Leibowitz JL, Spearie CA, et al. Acute dietary nitrate intake improves muscle contractile function in patients with heart failure: a double-blind, placebo-controlled, randomized trial. Circ Heart Fail 2015; 85: 914-20.
91. Borghi C, Cicero AF. Nutraceuticals with clinically detectable blood pressure lowering effect: a review of available randomized clinical trials and their meta-analyses. Br J ClinPharmacol 2017; 83(1): 163-71.
92. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289(2): 194-202.
93. Tuppin P, Riviere S, Rigault A, et al. Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database. Arch Cardiovasc Dis 2016; 109(6-7): 399-411.
94. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63(12): 1123-33.
95. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol 2014; 171(3): 368-76.
96. Yao G, Freemantle N, Flather M, et al. Long-term costeffectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model. Pharmacoeconomics 2008; 26: 879-89.
97. Lee WC, Chavez YE, Baker T, Luce BR. Economic burden of heart failure: a summary of recent literature. Heart Lung. 2004; 33(6): 362-71.
98. Qian C, Wei B, Ding J, Wu H, Wang Y. The efficacy and safety of iron supplementation in patients with heart failure and iron deficiency: A systematic review and Meta-analysis. Can J Cardiol 2016; 32(2): 151-9.